Nanoscale Horiz., 2021, Advance Article
DOI: 10.1039/D0NH00550A, Communication
DOI: 10.1039/D0NH00550A, Communication
Open Access
  This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.Luís Estronca, Vitor Francisco, Patrícia Pitrez, Inês Honório, Lara Carvalho, Helena Vazão, Josephine Blersch, Akhilesh Rai, Xavier Nissan, Ulrich Simon, Mário Grãos, Leonor Saúde, Lino Ferreira
The vascular bioactivity/safety of nanomaterials is typically evaluated by animal testing, which is of low throughput and does not account for biological differences between animals and humans such as ageing, metabolism and disease profiles.
To cite this article before page numbers are assigned, use the DOI form of citation above.
The content of this RSS Feed (c) The Royal Society of Chemistry
The vascular bioactivity/safety of nanomaterials is typically evaluated by animal testing, which is of low throughput and does not account for biological differences between animals and humans such as ageing, metabolism and disease profiles.
To cite this article before page numbers are assigned, use the DOI form of citation above.
The content of this RSS Feed (c) The Royal Society of Chemistry